Skip to main content
Atrás
AVBP logo

ArriVent BioPharma, Inc. Common Stock

Calidad de datos: 100%
AVBP
NASDAQ Healthcare Biotechnology
$22.75
▲ $0.80 (3.64%)
Cap. Mercado: 1.01B
Rango del Día
$22.34 $22.98
Rango de 52 Semanas
$15.47 $27.22
Volumen
232,221
Promedio 50D / 200D
$22.89 / $21.19
Cierre Anterior
$21.95

Quick Summary

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Healthcare (627 pares)

Métrica Acción Mediana del Sector
P/E -6.1 0.3
P/B 3.3 3.0
ROE % -58.9 3.7
Net Margin % 3.8
Rev Growth 5Y % 10.0
D/E 0.0 0.2

Precio Objetivo de Analistas

Hold
$44.00 +93.4%
Low: $43.00 High: $45.00
EPS Futuro
-$3.76
Ingresos Est.
125,000.0

Estimaciones de Ganancias

Período EPS Est. Ingresos Est. Analistas
FY2030 $3.55
$1.66 – $5.62
433.92M 5
FY2029 $0.84
$0.39 – $1.34
266.77M 2
FY2028 -$1.47
-$3.61 – $1.91
130.96M 7

Earnings Surprises

Last 8 quarters
Quarter Est. EPS Actual EPS Surprise
2026-03-05 -$0.85 -$0.78 +7.8%
2025-11-10 -$0.78 -$0.83 -6.4%
2025-08-11 -$0.70 -$0.90 -28.6%
2025-05-12 -$0.66 -$1.90 -187.9%
2025-03-03 -$0.78 -$0.60 +23.1%
2024-11-14 -$0.82 -$0.61 +25.6%
2024-08-14 -$0.65 -$0.65 0.0%
2024-05-08 -$0.84 -$0.70 +16.7%

Dividend History

Yield

0.00%

Payout Ratio

0.00%

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

Puntos Clave

Debt/Equity of 0.00 — conservative balance sheet
Negative free cash flow of -160.59M

Crecimiento

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Calidad

Return on Equity
-58.88%
ROIC-43.34%
Net MarginN/A
Op. MarginN/A

Seguridad

Debt / Equity
0.00
Current Ratio12.83
Interest Coverage0.00

Valoración

P/E Ratio
-6.05
Forward P/EN/A
P/B Ratio3.27
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0.0 Net Income (TTM) -166.31M
ROE -58.88% ROA -49.92%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -160.59M
ROIC -43.34% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.00 Current Ratio 12.83
Interest Coverage 0.00
Dividends
Dividend Yield 0.00% Payout Ratio 0.00%
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -6.05 Forward P/E N/A
P/B Ratio 3.27 P/S Ratio N/A
PEG Ratio -0.07 Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 8044.70 Fwd Earnings Yield N/A
FCF Yield -15.97%
Market Cap 1.01B Enterprise Value 960.06M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 0.0 0.0 0.0 0.0 0.0
Net Income -166.31M -80.49M -69.33M -36.91M -51.61M
EPS (Diluted) -4.32 -2.56 -2.17 -1.10 -40.44
Gross Profit 0.0 0.0 0.0 0.0 0.0
Operating Income -177.53M -94.31M -74.59M -36.91M -8.70M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 333.17M 274.94M 163.10M 182.83M 43.04M
Total Liabilities 25.95M 17.29M 11.80M 8.37M 1.82M
Shareholders' Equity 307.22M 257.65M 151.30M 174.46M 41.22M
Total Debt 14,000.0 176,000.0 317,000.0 139,000.0 0.0
Cash & Equivalents 45.54M 74.29M 150.39M 163.37M 37.28M
Current Assets 332.90M 226.98M 159.97M 182.62M 42.95M
Current Liabilities 25.95M 17.27M 11.62M 8.36M 1.82M